SOPHiA GENETICS CSO awarded options and RSUs
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity awards consisting of stock options and restricted stock units as part of his compensation.
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 82,335 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. He also received 56,468 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030. These are awards, not open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 138,803 shares
Grant/Award
2 txns
Insider
Puylaert Kevin
Role
Chief Sales Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 82,335 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 56,468 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 82,335 contracts (Direct);
Ordinary Shares — 56,468 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
- F2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
Stock options granted: 82,335 options
Option exercise price: $5.04 per share
RSUs granted: 56,468 RSUs
+5 more
8 metrics
Stock options granted
82,335 options
Right to buy ordinary shares at $5.04, grant on April 2, 2026
Option exercise price
$5.04 per share
Exercise price for 82,335 options expiring April 2, 2036
RSUs granted
56,468 RSUs
Restricted stock units under 2021 Equity Incentive Plan
RSU vesting start
25% on April 2, 2027
Initial vesting date for RSU grant
RSU remaining vesting
75% through April 2, 2030
Vests in equal quarterly installments, service-based
Option vesting schedule
25% on April 2, 2027
Remainder vests in equal monthly installments through April 2, 2030
Options expiration
April 2, 2036
Final expiration date of 82,335 share options
Shares following RSU grant
56,468 shares
Total ordinary shares reported following RSU acquisition entry
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vesting, share option, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"RSU grant made under the Issuer's 2021 Equity Incentive Plan."
vesting financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercisable financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did SOPHiA GENETICS (SOPH) disclose in this Form 4 filing?
SOPHiA GENETICS disclosed that Chief Sales Officer Kevin Puylaert received new equity awards, including stock options and restricted stock units. These grants are compensation-related and do not involve any open-market buying or selling of the company’s shares by the executive.
How many stock options did Kevin Puylaert receive from SOPHiA GENETICS (SOPH)?
Kevin Puylaert received 82,335 stock options, each giving the right to buy one ordinary share at $5.04 per share. These options expire on April 2, 2036 and vest over time, starting in 2027 and continuing monthly through 2030.
What are the terms of the restricted stock units granted to SOPHiA GENETICS (SOPH) executive Kevin Puylaert?
He received 56,468 restricted stock units (RSUs), each representing one ordinary share, under the 2021 Equity Incentive Plan. Twenty-five percent vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on continued service.
Did the SOPHiA GENETICS (SOPH) Form 4 show any stock sales or purchases by Kevin Puylaert?
The filing shows no open-market stock purchases or sales by Kevin Puylaert. All reported transactions are compensation grants of stock options and restricted stock units, both recorded at a transaction price of $0.00 per share for reporting purposes.
When do Kevin Puylaert’s stock options at SOPHiA GENETICS (SOPH) vest and become exercisable?
The share options vest as to 25% on April 2, 2027, then continue vesting in equal monthly installments through April 2, 2030. He must remain in service with the company through each vesting date for the corresponding portion to become exercisable.
What conditions apply to Kevin Puylaert’s RSU grant at SOPHiA GENETICS (SOPH)?
Each RSU represents a contingent right to receive one ordinary share, subject to his continued service with SOPHiA GENETICS. Vesting occurs 25% on April 2, 2027, and the remaining 75% in equal quarterly installments through April 2, 2030.
AI-generated analysis. How Rhea-AI works. Not financial advice.
